Drugs Controller General of India

Zydus Cadila seeks emergency authorisation for ZyCoV-D COVID-19 vaccine for 12 years, above

The company's three-dose regimen Covid-19 vaccine is the second indigenously developed vaccine to apply for such permission after Bharat Biotech's Covaxin.

published on : 1st July 2021

Zydus Cadila seeks DCGI nod for human clinical trials of antibodies cocktail to treat COVID-19

Cadila Healthcare is the listed entity of the group. ZRC-3308 has been found to be safe and well tolerated in animal toxicology studies.

published on : 27th May 2021

Irresponsible: Maharashtra COVID task force member on Ramdev's remarks against allopathy

IMA took strong exception to Ramdev's comments in a viral video where he said allopathy is a "stupid science" and lakhs of people have died after taking allopathic medicines.

published on : 22nd May 2021

Will examine data of 2-DG drug for adding it to national COVID treatment protocol: Government

At a press conference, NITI Aayog member (health) Dr V K Paul said Drugs Controller General of India (DCGI) has granted permission for emergency use of the drug after looking at the data.

published on : 18th May 2021

First batch of anti-COVID drug 2-DG to be released on Monday

The Drugs Controller General of India (DGCI) has approved the oral drug for emergency use as an adjunct therapy in moderate to severe coronavirus patients, the defence ministry said.

published on : 16th May 2021

DCGI approves Phase two, three clinical trials of COVAXIN on children aged two to 18 years

Bharat Biotech will conduct trials in 525 healthy volunteers. the vaccine will be given by intramuscular route in two doses at day 0 and day 28.

published on : 13th May 2021

Vaccine shortage: Serum Institute to produce 10 crore doses by August, Bharat Biotech promises 7.8 crore jabs

The sources said the Union Health Ministry and the office of Drugs Controller General of India had sought from both the firms their production plan for June, July, August and September.

published on : 13th May 2021

India gets third COVID-19 vaccine as DCGI approves restricted emergency use of Sputnik V

According to sources, around 10 crore doses of the Sputnik V vaccine is likely to be imported for emergency use in the country in the next six to seven months.

published on : 13th April 2021

COVID-19: Government's expert panel allows clinical trials for third dose of Covaxin

Further, Bharat Biotech was asked to present the details of the primary and secondary objectives and various assessments to be carried out in the subjects.

published on : 2nd April 2021